With the recent completion of a working draft of the human genome sequence, attention is turning once again to the controversial issue of gene patenting. In response to mounting criticism about the ease with which some groups have been able to apply for and receive patents on poorly characterized human gene sequences, the US Patent and Trademark Office (USPTO) has recently released new guidelines that will affect the outcome of gene patent applications.
In order for a gene patent to be approved, a patent will have to not only provide an adequate description of a gene, but also link the gene with a specific, useful application. With the new guidelines, the USPTO again rejected all arguments against the patenting of genes. "The eligibility of genes to be patented is firmly based in legislative history and judicial law," explains John Doll, director of biotechnology at USPTO.
In the United States, a patent application directed to a genetic sequence has several hurdles to overcome: it has to be novel (for example, a genetic sequence that has not been previously published), not obvious to people working in the field, and useful. This final requirement -utility -is the central focus of the new guidelines. While it is clear that the description of a human gene encoding a medically useful protein is patentable whereas raw DNA sequence data are not, the new guidelines provide a framework for determining where to draw the line between the two extremes.
Patent applicants must be able to show specific, credible, and substantial utility for gene sequences. Specific utility means that the applicant has to know what the sequence does. Credible utility means that the claim must be believable to people who know the field. Lastly, the substantial utility criterion, which was introduced with the new guidelines, states that the sequence must have a 'real-world' use -in other words, there has to be a clearly defined use for it in commerce.
Patent applicants must show specific, credible, and substantial utility for gene sequences For example, an expressed sequence tag (EST) can be patented if it provides the basis for a diagnostic test. On the other hand, the argument that an EST is useful because it can allow scientists to find the entire gene and is thus a tool for further research is unlikely to meet the utility requirement. The scope of an EST patent would also be limited to the sequence included within the EST and not the sequence surrounding it (for example, an entire gene if the EST happens to fall within a gene).
'Gene patents' is a broad term that covers patenting of genetic sequences and the processes for isolating them. From 1997 to 1999, more than 9,000 gene-related patents were issued by the USPTO (see Figure) , about one third of those in 1999 alone. The US biotechnology company Incyte Genomics (Palo Alto, California) tops the list among gene patent holders with over 500 gene-related patents in the United States. The company says it has filed patent applications covering portions of more than 50,000 genes, including 7,000 that are full length. While Celera Genomics (Rockville, Maryland), the company lead by J. Craig Venter that recently released its assembly of the human genome sequence, has filed provisional patent applications on at least 6,500 gene sequences, the company has yet to be awarded any human gene patents. But the rush to patent human genes is not confined to the biotechnology and pharmaceutical industries. Universities and government agencies are also involved in the race to patent genes; the University of California and the National Institutes of Health are the two most active.
According to Lila Feisee, director of intellectual property for the Biotechnology Industry Organization (BIO), members of the biotechnology industry generally approve of the new USPTO guidelines. Critics, however, believe that the bar is still not high enough. For example, critics from the NIH have said that computer homology studies of gene sequences are not sufficient for determining gene function and that the new standards should not allow claims of 'predicted' function. The USPTO position, however, is that, under US law, a utility must be credible but does not have to be proven to an absolute certainty. According to the new guidelines, "when a patent application claiming a nucleic acid 
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asserts a specific, substantial, and credible utility, and bases the assertion upon homology to existing nucleic acids or proteins having an accepted utility, the asserted utility must be accepted by the examiner unless the Office has sufficient evidence or sound scientific reasoning to rebut such an assertion."
The entire concept that genes should be patented has been the subject of heated debate. When the USPTO originally proposed the utility guidelines in December 1999, it received several comments from the public arguing against the notion of awarding patents for genetic materials based on the premise that genes are part of nature and not an invention. Such arguments were rejected by the USPTO on the grounds that DNA fragments that are isolated, cloned, and purified are, from the perspective of patent law, just another man-made invention. The practice of patenting pieces of nature is not new. Indeed, according to the USPTO, Louis Pasteur received US Patent 141,072 in 1873, claiming "yeast, free from organic germs of disease as an article of manufacture."
Another criticism of gene patents focuses on concerns that they will stifle laboratory research. A gene patent entitles the owner to 20-year patent protection from others working on the same gene. Some scientists argue that current patent law discourages scientists from developing diagnostic tests using genes that have been patented for fear of being shut down. The USPTO addressed these concerns by saying that "it is somewhat rare for academic researchers to be sued by commercial patent owners for patent infringement. Most inventions are made available to academic researchers on very favorable licensing terms, which enable them to continue their research." John F. Merz, an assistant professor of bioethics at the University of Pennsylvania, disagrees. "Myriad Genetics [the company that holds patents to the breast cancer genes BRCA1 and BRCA2] narrowly defined what they considered to fall outside of the ambit of patent protection: funded, hypothesis-driven research wherein no results of testing would be provided to patients/subjects. So, did they stop doctors from doing studies? I have no doubt," he says. Michael Watson, a professor of pediatrics at Washington University in St. Louis concurs. According to Watson, "while basic research is protected, the clinical investigative stage during which the analytical and clinical performance characteristics of tests are determined (and which may take many years) is directly impacted."
Another concern is that as the number of genes receiving patents grows, genetic testing of patients will become prohibitively expensive, with physicians having to pay a royalty for every genetic test performed. Biotechnology companies counter by suggesting that without patent protection, research and development costs will not be recouped and there will be little incentive for investments within the biotechnology industry. Furthermore, representatives from biotechnology companies will point out that many companies will offer favorable licensing terms to physicians.
A recent example is a deal that was struck between the UK's National Health Service (NHS) and Rosgen, the biotechnology company that holds exclusive license to market Myriad's genetic tests for breast cancer in the UK. The company, based at the Roslin campus where Dolly the sheep was cloned, agreed that there would be no royalty charges for tests performed by the NHS. The company, however, plans to charge private patients from £450 ($700) per test.
The debate over gene patents is unlikely to end anytime soon. Watson, who helped draft a resolution endorsed by the American College of Genetics calling for an end to human gene patenting, is pushing for strong action from congressional and other federal oversight bodies. In 1996, pressure from physicians and patient groups resulted in Congress passing a law, the 'Ganske legislation', which holds physicians and medical institutions free of liability for infringing patents on medical processes. Watson thinks the legislation should now be extended to genetic testing. "This allows the patent protection for future development to remain, while protecting the practitioner from liability for [infringement] ." Laura Bonetta is a freelance science writer based in the Washington DC area.
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